Qiagen NV, a Netherlands-based provider of sample and assay technologies, is to acquire the privately-held SABiosciences Corp of the US for $90 million in cash. The deal will give the Dutch company access to assay panels to analyse new drug targets. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals